Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104. Background: PRRT using Lutetium Lu 177 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results